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Abstract
Background. Etiological research of depression and anxiety disorders has been hampered by
diagnostic heterogeneity. In order to address this, researchers have tried to identify more
homogeneous patient subgroups. This work has predominantly focused on explaining inter-
personal heterogeneity based on clinical features (i.e. symptom profiles). However, to explain
interpersonal variations in underlying pathophysiological mechanisms, it might be more
effective to take biological heterogeneity as the point of departure when trying to identify sub-
groups. Therefore, this study aimed to identify data-driven subgroups of patients based on
biomarker profiles.
Methods. Data of patients with a current depressive and/or anxiety disorder came from the
Netherlands Study of Depression and Anxiety, a large, multi-site naturalistic cohort study
(n = 1460). Thirty-six biomarkers (e.g. leptin, brain-derived neurotrophic factor, tryptophan)
were measured, as well as sociodemographic and clinical characteristics. Latent class analysis
of the discretized (lower 10%, middle, upper 10%) biomarkers were used to identify different
patient clusters.
Results. The analyses resulted in three classes, which were primarily characterized by different
levels of metabolic health: ‘lean’ (21.6%), ‘average’ (62.2%) and ‘overweight’ (16.2%).
Inspection of the classes’ clinical features showed the highest levels of psychopathology, sever-
ity and medication use in the overweight class.
Conclusions. The identified classes were strongly tied to general (metabolic) health, and did
not reflect any natural cutoffs along the lines of the traditional diagnostic classifications. Our
analyses suggested that especially poor metabolic health could be seen as a distal marker for
depression and anxiety, suggesting a relationship between the ‘overweight’ subtype and intern-
alizing psychopathology.
Introduction
Depression and anxiety are highly prevalent and associated with a substantial burden on both
patients, their caregivers and society as a whole (Kessler, 2012; Whiteford et al., 2016; World
Health Organization (WHO), 2016). The overlap between depressive and anxiety symptoms
and disorders is the rule rather than the exception, and much of the same treatments are cur-
rently used for patients in both diagnostics categories (Nutt et al., 2002; Hettema, 2008;
Goldberg, 2011). Despite the many research efforts that have been made over the past decades,
the etiological mechanisms underlying depressive and anxiety disorders are still poorly under-
stood, which is partially due to the heterogeneous nature of the patient population (Kendler,
2014; Monroe and Anderson, 2015), resulting in small to moderate observed treatments effects
(Turner and Rosenthal, 2008; Cuijpers et al., 2010; Cooney, 2013; Roest et al., 2015). Scientific
progress is more likely if the problem of diagnostic heterogeneity is effectively addressed.
Unfortunately, more homogeneous clinical subtypes have been shown to be weakly associated
with etiology, the course of illness, and treatment response (Baumeister and Parker, 2012).
Alternative data-driven subtype classifications based on cluster analyses (Lubke and
Muthén, 2005; Hastie et al., 2011; Van Loo et al., 2012), have also been shown to have limited
associations with specific etiological mechanisms (Van Loo et al., 2012; Marquand et al.,
2016). This limited association with etiology might be explained by the fact that these subtypes
are primarily optimized to differentiate between symptom patterns and not between biological
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mechanisms (Hasler et al., 2004). Subtypes might be more suit-
able to investigate etiological heterogeneity when biological pro-
files are used as the point of departure.
It has been acknowledged that theories assuming that there is a
single biological disturbance underlying depression in all patients
(e.g. monoamine deficiency) have limited validity (Kendell and
Jablensky, 2003; Hasler, 2010; Kapur et al., 2012). Rather, the spe-
cific disturbances are likely to differ between patients, even those
with similar symptomatology and/or diagnoses (Insel et al., 2010).
If we consider this, the low observed effect sizes in treatment trials
could be explained by the fact that only in part of the patients
treated with a certain compound (e.g. selective serotonin reuptake
inhibitors), the treatment actually affects their individual bio-
logical disturbances (Tang et al., 2010). Identification of more
homogeneous biomarker-based subtypes in the patient popula-
tion could help to gain more insight into patient-specific etio-
logical mechanisms and to better target treatments to those that
are likely to benefit (Meyer and Ginsburg, 2002; Bartova et al.,
2010; Leuchter et al., 2010; Simon and Perlis, 2010; Simon,
2011; e Silva, 2013; Miller and O’Callaghan, 2013; Ozomaro
et al., 2013; Cuijpers et al., 2016; Korte et al., 2015).
To our knowledge, the existence of depression/anxiety sub-
types with different biological disturbance profiles and their
manifest clinical characteristics have not been extensively studied
before. Therefore, this study aimed to identify biomarker-based
subtypes using latent class analysis (LCA) a large and well-
phenotyped sample of depressive and/or anxiety patients (n =
1460). In this sample, 36 biomarkers were measured, representing
different underlying mechanisms that have previously been
found to be relevant to depression and anxiety disorders (e.g.
hypothalamus-pituitary-adrenal axis function, inflammation).
Next, in order to investigate the clinical relevance and utility of
the identified biomarker-based subtypes, clinical characteristics
and symptomatology were compared across the identified classes.
Methods and materials
Participants and procedures
The Netherlands Study of Depression and Anxiety (NESDA) is a
multisite naturalistic cohort study that aims to examine the long-
term course of depressive and anxiety disorders. A detailed
description of the NESDA study design and sampling procedures
can be found elsewhere (Penninx et al., 2008). In brief, the
NESDA cohort consists of 2981 subjects, aged 18—65 years,
with (a history of) anxiety and/or depressive disorder and healthy
controls. The research protocol was approved by the Medical
Ethical Committees of participating institutes, and after complete
description of the study, all respondents provided written
informed consent. For the present study, all 1460 subjects with
a current (last month) diagnosis of a depressive or anxiety dis-
order according to the Composite International Diagnostic
Interview (CIDI; WHO version 2.1) were selected. For additional
analyses (see below), 634 healthy control subjects were added to
the dataset.
Measurements
During a 4-hour baseline assessment including interviews, a med-
ical examination, a cognitive computer task and collection of
blood samples, extensive information was gathered about key
(mental) health outcomes and demographic, psychosocial, clinical
and biological determinants. Additional measures (written ques-
tionnaires and saliva samples) were carried out at home by the
participants. Diagnostic and statistical manual of mental
disorders-fourth edition (DSM-IV) diagnoses of depressive
[minor depression, dysthymia and major depressive disorder
(MDD)] and anxiety disorders (generalized anxiety disorder,
social phobia, agoraphobia and panic disorder) were established
using the Composite International Diagnostic Interview (CIDI)
2.1. Depression symptom severity was measured with the
30-item Inventory of Depressive Symptomatology Self Report
(IDS-SR) (Rush et al., 1996). Anxiety symptom severity was mea-
sured with the Beck Anxiety Inventory (BAI) (Beck et al., 1988).
Sociodemographic information included age, sex, number of
chronic diseases, drinking and smoking behavior. The biological
data consisted of waist circumference, body mass index (BMI),
blood pressure (systolic/diastolic and the ankle-brachial index),
heart rate variability and markers from blood and saliva samples.
A summary of the biological methods is provided below. For more
details, see online Supplementary Table S1.
Blood markers
Venous blood was drawn prior to the interview session (between
8:00 and 9:00 am) after an overnight fast. Venous blood samples
were transferred to a local lab for routine assessments; serum and
plasma were spun down within an hour and stored at −80 °C for
later analyses. The routine assays included hematological variables
(hemoglobin, hematocrit, and erythrocyte count), liver function
(γ-glutamyltransferase, aspartate aminotransferase, alanine ami-
notransferase) and kidney function (creatinine), as well as mar-
kers related to the metabolic syndrome (MetS) and obesity
(glucose, cholesterol, triglycerides, HDL- and LDL-cholesterol,
thyroid-stimulating hormone, free thyroxine). Additional biomar-
kers are described below. Most of these markers’ associations with
mental-health outcomes have previously been established (Chaves
et al., 2004; Vancampfort et al., 2014; Hiles et al., 2016).
Inflammation. C-reactive protein (hsCRP) was measured in
duplicate by an in-house enzyme-linked immunosorbent assay
(ELISA), based on purified protein and polyclonal anti-hsCRP
antibodies (Dako, Glostrup, Denmark). Plasma IL-6 levels were
measured in duplicate by a high sensitivity ELISA (PeliKine
Compact TM ELISA, Sanquin, Amsterdam, The Netherlands).
Plasma tumor necrosis factor alpha (TNF-α) levels were assayed
in duplicate using a high-sensitivity solid phase ELISA (Quanti-
kine® HS Human TNF- α Immunoassay, R&D systems Inc,
Minneapolis, MN, USA). Tryptophan and (OH-)kynurenine con-
centrations were assayed by an automated online solid-phase
extraction-liquid chromatographic-tandem mass spectrometric
(XLC-MS/MS) method. Both inflammation and degradation of
tryptophan along the kynurenine pathway have been found to
be associated with depression in this sample (Lamers et al.,
2013; Quak et al., 2014).
Neuroplasticity. Brain-derived neurotrophic factor (BDNF) pro-
tein levels were measured in serum samples using the Emax
Immuno Assay system from Promega (Madison, WI, USA).
IGF-I (nmol/l) was assayed centrally by chemiluminescence
immunoassay of EDTA plasma on the Liaison autoanalyzer
(DiaSorin, S.p.A., Italy). Both measures have previously been
found to be associated with depression with melancholic features
in this sample (Patas et al., 2014).
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Mineral balance. Measurements of parathyroid hormone (PTH)
were performed at the Endocrine Laboratory of the VU
University Medical Center. PTH levels were measured in EDTA
plasma using an intact PTH assay. Intact PTH levels were
measured using an immunometric assay (Architect, Abbott
Diagnostics, Abbott Park, IL). Vitamin D was measured based
on circulating levels of 25(OH)D, extracted and analysed by
XLC-MS/MSa (Spark Holland, Emmen, the Netherlands) and
coupled to a Quattro Premier XE tandem mass spectrometer
(Waters Corp., Milford, MA, USA). Vitamin D has previously
been found to be associated with depression in this sample
(Milaneschi et al., 2014).
Steroid hormones. Dehydroepiandrosterone and its sulfate conju-
gate (DHEA/-S) were determined using a delayed one-step
immunoassay with a chemiflex assay protocol. Sex Hormone
Binding Globulin (SHBG) was determined using a two-step
immunoassay with a chemiflex assay protocol. Total estradiol
(E2) was determined using a delayed one-step immunoassay
with a chemiflex assay protocol. Previously, steroid hormones
were found to be associated with anxiety and depression in this
sample (Giltay et al., 2012; Morita et al., 2014).
Leptin. Plasma leptin concentrations were measured in EDTA
plasma using an ELISA kit (Human Leptin ELISA Kit; Linco
Research, Inc, St. Charles, Missouri). Leptin has previously been
found to be associated with depression (with atypical features)
in this sample (Milaneschi et al., 2017).
Saliva markers
On a single day, prior to the first face-to-face assessment session,
participants themselves collected saliva samples at home using
Salivettes (Sarstedt AG and Co, Nürmbrecht, Germany).
Measurements were taken at awakening [T1], 30 [T2], 45 [T3]
and 60 [T4] minutes later, and in the evening (22:00 [T5] and
23:00 [T6]). Additionally, the dexamethasone suppression test
(Carroll, 1982) was carried out by oral administration of a
0.5 mg dexamethasone pill directly after T6 and a final cortisol
measurement the next morning at awakening (T7). The saliva
samples were used to assess levels of cortisol, amylase and testos-
terone. These measures have previously been observed to be asso-
ciated with depression and anxiety in this sample (van Santen
et al., 2011; Giltay et al., 2012; Veen et al., 2013).
Heart rate variability
A heart rate recording was performed with the Vrije Universiteit
Ambulatory Monitoring System (Cuijpers et al., 2013)
(VU-AMS). Subjects were wearing the VU-AMS device during
a large part of the NESDA baseline assessment, while participat-
ing in different assessment parts (i.e. medical examination, inter-
viewing, and a computer task). The start of the various assessment
parts was marked with an event marker to divide the total record-
ing into fixed periods. Movement registration through vertical
accelerometry was used to excise periods where subjects were
non-stationary. For this project, VU-AMS heart rate variability
(HRV) during resting baseline, and HRV change from baseline
to two stress conditions (interview and stressful computer task)
were used. HRV has previously been found to be associated
with depression in this sample (Licht et al., 2008).
Statistical analyses
LCA was used to identify data-driven subgroups with distinct bio-
logical profiles. LCA assumes that an unobserved, latent categor-
ical variable explains the association among a set of observed
variables. The input variables are listed in online Supplementary
Table S1. Models with increasing numbers of classes were esti-
mated and compared. The optimal model selection was based
on the highest entropy and the lowest Akaike Information
Criterion (AIC) and Bayesian Information Criterion (BIC).
Relative entropy is a measure of classification accuracy (range:
0–1), with values closer to 1 indicating greater accuracy. Lower
AIC and BIC values indicate that the model provides a better
description of the data. Because these measures do not always
agree, parsimony and interpretability were also taken into
account. To avoid convergence on a solution at a local maximum
(Nylund et al., 2007) LCA was run using up to 1000 random start-
ing values and 250 final stage optimizations. LCA was conducted
using Mplus version 5 (Muthen and Muthen, 2007). To investi-
gate the influence of the different variables on the model solution
Cramer’s V (Cramér, 1946) was calculated for each biomarker
variable.
After the optimal model was identified, subjects were assigned
to their most likely class based on their highest posterior class
probability. Differences between classes (in biomarkers, sociode-
mographics, DSM-IV diagnoses and clinical characteristics)
were investigated by using two-tailed χ2 statistics for categorical
variables and one-way analysis of variance statistics for continu-
ous variables, or by using the Kruskall–Wallis test if the outcomes
were not normally distributed. The False Discovery Rate control-
ling procedure was used to counteract the problem of multiple
comparisons (Benjamini and Hochberg, 1995). All comparisons
were conducted using SPSS for Windows, version 23 (IBM Inc.,
USA). To evaluate if the identified class structure was specifically
informative about the biological heterogeneity in depressed/anx-
ious patients or was more broadly reflective of normal biological
variations in the population as a whole, all analyses were rerun in
a dataset including both patients and healthy controls (n = 2094).
Data preprocessing
Clinically determined cut-off values to categorize the biomarker
variables were available for some but not all biomarkers.
Therefore, an alternative approach was taken, categorizing every
variable based on percentiles, with the lowest and highest scoring
10th percentile of all subjects being coded as −1 and 1, respect-
ively, and the middle 80% being coded 0. The 10th percentile cut-
off was chosen to make sure that especially the more extreme,
potentially clinically relevant variations in biomarker levels
would be represented in the eventual LCA model. Setting the cut-
offs at higher percentile values would lead to biomarker variables
with more subjects in both the lower and upper category, but with
a more within-category variation of biomarker levels. This makes
the categorization potentially less useful for differentiation
between subjects with distinct biomarker patterns as relevant
interpersonal differences are eliminated by pooling patients with
different biomarker levels in the same category. Indeed, explora-
tory analyses using 25th and 50th percentiles as cutoffs led models
with many classes (i.e. the AIC and BIC kept decreasing with each
class addition) that could not be easily distinguished from each
other in terms of their specific biomarker patterns. In the final
coding scheme, the number of subjects per decile varied between
Psychological Medicine 3
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8% and 12%, because in some cases a large number of subjects
had the same score, and we chose to use the percentile closest
to 10. The above-described coding was done separately for differ-
ent sex/age (<30, 30–50, >50) strata, because the distributions of
some biological variables are known to differ across sex and age
(e.g. testosterone). Differences between classes on other
potentially relevant covariates were investigated after identifica-
tion of the optimal latent class model.
To ensure that the model solution would not be driven by the
fact that some variables were essentially measuring the same
thing, all variables with a correlation above 0.75 before recoding
were summed after categorization (i.e. the hematological markers,
the heart rate variability reactivity in both test conditions, systolic
and diastolic blood pressure, aspartate and alanine aminotransfer-
ase). Subjects with a score of ⩽−1 got a value of −1, those with a
score of 0 got a value of 0 and subjects with a score of ⩾1 got a
value of 1 on a newly constructed compound variable. Recoding
was done using SPSS for Windows, version 23 (IBM Inc., USA).
The final dataset included 36 biological variables.
Results
The LCA results are shown in Table 1. The lowest BIC combined
with adequate entropy indicated that the 3-class model best
described the data. Although the AIC decreased for the more
complex models up to six classes, these models were less optimal
in terms of parsimony and showed only marginally higher
Table 1. Statistics for LCA models with different numbers of classes, based on
the sample of subjects with current psychopathology (n = 1406)
Classes DF AIC BIC H
2 149 61 930.889 62 718.531 0.725
3 224 61 360.457 62 544.564a 0.765
4 299 61 079.887 62 660.458 0.756
5 374 60 934.908 62 911.944 0.765
6 449 60 807.111a 63 180.612 0.797a
aMost favorable score.
DF, Degrees of Freedom; AIC, Akaike Information Criterion; BIC, Bayesian Information
Criterion; H, Entropy.
Fig. 1. Probabilities to score in the lowest (left) or highest (right) 10-th percentile of each variable for the different latent classes in the sample including subjects
with current psychopathology. A = Lean (21.6%), B = Average (62.2%), C = Overweight (16.2%). Color groups consist of biomarkers with similar themes, as indicated
in online Supplementary Table S1. Abbreviations: Blood pressure, combination of systolic and diastolic pressure; T4, free thyroxine; TSH, thyroid stimulating hor-
mone; PTH, parathyroid hormone; CAR, cortisol awakening response; AUCg, area under the curve with respect to the ground, AUCi, area under the curve with
respect to increase; DHEA(-S), dehydroepiandrosterone(-sulphate); HRV, heart rate variability; HRV reactivity, combination of HRV reactivity in both stress situations;
BDNF, brain-derived neurotrophic factor, IGF-1 insulin-like growth factor 1; E2, estradiol; SHBG, sex hormone binding globulin; IL-6, interleukin 6; TNFa, tumor
necrosis factor alpha; hsCRP, C-reactive protein; GAMMA, gamma-glutamyltransferase; ASAT/ALAT, combination of aspartate aminotransferase and, alanine amino-
transferase; hematology, combination of hemoglobin, hematocrit, and erythrocyte values.
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Table 2. Distribution of biomarkers across identified classes in the sample of subjects with current psychopathology
Hypothesis Variable (Abbreviation, unit) Lean (N = 311) Average (N = 910) Overweight (N = 239) p*
Neuroplasticity Brain-derived neurotrophic factor (BDNF, ng/ml) 8.66 (3.13) 9.28 (3.66) 9.19 (3.67) 0.033
Insulin-like Growth Factor 1 (IGF-1, nmol/l) 25.1 (8.7) 26.88 (8.42) 23.15 (7.87) 0.000a,b
Mineral balance Vitamin D (nmol/l) 62.84 (33.92) 63.14 (27.52) 47.02 (23.25) 0.000a,c
Parathyroid hormone (PTH, pmol/l) 5.25 (2.22) 5.60 (2.24) 7.16 (3.18) 0.000a,b,c
Inflammation C-reactive protein (hsCRP, mg/l) 1.58 (2.82) 2.68 (4.9) 6.65 (7.82) 0.000a,b,c
Interleukin 6 (IL-6, pg/ml) 1.05 (1.18) 2.00 (23.44) 1.81 (3.67) 0.000a,b,c
Tumor necrosis factor alpha (TNF-α, pg/ml) 0.87 (0.94) 1.13 (1.54) 1.25 (1.32) 0.000a,b,c
Tryptophan (μmol/l) 58.75 (11.54) 65.57 (13.17) 65.58 (15.51) 0.000,a,c
Kynurenine (μmol/l) 1.84 (0.53) 2.32 (0.59) 2.48 (0.84) 0.000,a,c
3-hydroxykynurenine (nmol/l) 24.18 (11.42) 32.06 (13.08) 37.81 (19.79) 0.000a,b,c
Stress response Area under the curve with respect to the ground
(AUCg, μg/dl/h)
19.98 (7.18) 19.34 (7.35) 17.48 (6.41) 0.012a,c
Area under the curve with respect to the
increase (AUCi, μg/dl/h)
3.30 (5.92) 2.43 (6.68) 1.61 (5.38) 0.047
Evening cortisol (nmol/l) 5.92 (3.76) 5.29 (3.23) 5.36 (2.63) 0.017a
Dexamethasone (DST) cortisol-suppression 0.38 (0.17) 0.39 (0.24) 0.31 (0.25) 0.001a,c
Heart rate
variability
Mean root mean square of successive
differences (RMSSD)
47.53 (39.11) 41.60 (31.63) 31.91 (28.69) 0.000a,b,c
Difference from baseline to computer task 8.93 (18.94) 4.80 (23.4) 0.65 (22.5) 0.000a,b,c
Difference from resting baseline to interview 6.65 (14.13) 3.59 (17.5) 0.40 (16.7) 0.000a,b,c
Hematology Hemoglobin (Hob, nmol/l) 8.50 (0.80) 8.72 (0.78) 8.76 (0.89) 0.000a,c
Hematocrit (HT, L/L) 0.40 (0.04) 0.41 (0.03) 0.42 (0.04) 0.000a,c
Erythrocytes (×10^12/l) 4.48 (0.42) 4.65 (0.4) 4.75 (0.43) 0.000a,b,c
Steroid hormones Dehydroepiandrosterone (DHEA, nmol/ml) 25.50 (16.21) 22.49 (16.15) 19.08 (16.04) 0.000a,b,c
Dehydroepiandrosterone sulphate (DHEA-S,
μmol/l)
6.55 (3.61) 6.25 (3.65) 5.39 (3.66) 0.000a,c
Sex hormone-binding globulin (SHBG, nmol/l) 85.38 (66.9) 60.69 (51.65) 45.29 (39.04) 0.000a,b,c
Estradiol (E2, nmol/l) 0.49 (5.37) 0.26 (2.69) 0.17 (0.18) 0.088
Testosterone (nmol/l) 10.52 (11.3) 8.54 (8.62) 7.24 (7.54) 0.001a,b
Kidney function Creatinine (mg/dl) 0.73 (0.14) 0.76 (0.15) 0.76 (0.26) 0.007a
Liver function Gamma-glutamyltransferase (gamma-GT, U/L) 22.19 (27.56) 22.66 (17.67) 43.67 (39.75) 0.000a,b,c
Alanine aminotransaminase (ALAT, U/L) 19.29 (11.74) 22.91 (16.43) 34.95 (28.54) 0.000a,b,c
Aspartate aminotransferase (ASAT, U/L) 23.83 (9.86) 25.45 (10.61) 29.69 (13.73) 0.000a,b,c
Metabolic
markers
Waist circumference (cm) 77.85 (9.30) 88.88 (10.65) 108.43 (14.06) 0.000a,b,c
Body Mass Index 21.45 (2.77) 25.33 (3.55) 33.13 (5.81) 0.000a,b,c
Glucose (mmol/l) 5.01 (1.15) 5.16 (0.77) 5.74 (1.58) 0.000a,b,c
Low-density lipoproteins (LDL, mmol/l) 2.73 (0.91) 3.22 (0.98) 3.40 (0.99) 0.000a,b,c
High-density lipoproteins (HDL, mmol/l) 1.85 (0.50) 1.59 (0.39) 1.38 (0.40) 0.000a,b,c
Triglycerides (mmol/l) 0.97 (0.51) 1.29 (0.81) 1.96 (1.12) 0.000a,b,c
Blood pressure, systolic (Bp, mm Hg) 130.41 (17.5) 136.37 (20.01) 144.04 (17.58) 0.000a,b,c
Blood pressure, diastolic (Bp, mm Hg) 78.45 (9.74) 82.11 (11.29) 88.48 (10.62) 0.000a,b,c
Ankle brachial pressure index (ABPI) 1.14 (0.15) 1.14 (0.16) 1.15 (0.16) 0.345
Leptin (μg/l) 7.26 (6.60) 14.94 (10.49) 31.06 (18.28) 0.000a,b,c
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entropy. For each class, Fig. 1 shows the probabilities of biomarker
scores in the top or bottom 10th percentile. Table 2 shows the
distribution of biomarkers across the three latent classes. Most
biomarkers differed among classes, with the notable exception
of the cortisol-related biomarkers. Waist circumference, BMI
and leptin had the largest effect (Cramer’s V > 0.5) on the
model solution and were used to inform class labeling. Other vari-
ables (e.g. measures on inflammation and steroid hormones)
showed smaller, but still meaningful, variation between classes
(Cramer’s V = 0.335–0.209, see Table 3).
The first class was labeled ‘lean’ (n = 311) because it was asso-
ciated with a healthy BMI and a comparatively high probability of
being in the bottom 10th percentile for the obesity/MetS markers.
The second class was labeled ‘average’ (n = 910) because it showed
a low probability for extreme scores on any of the biomarkers. The
third class was labeled ‘overweight’ (n = 239) and was character-
ized by a pattern of probabilities almost perpendicular to the
lean class, with comparatively high probabilities to be in the
upper 10% on obesity and MetS-related markers.
Table 4 shows the distribution of clinical characteristics across
the three identified latent classes. As expected because of the pre-
stratified processing of the data, the classes did not differ with
respect to gender or age. The lean and average classes were similar
in terms of diagnoses, whereas subjects in the overweight class
were more likely to suffer from MDD. Persons in the overweight
class were also more likely to endorse the atypical depressive sub-
type and to use psychotropic medication, specifically tricyclic
antidepressants. Overweight subjects also had higher scores on
both the IDS and the BAI. The lean class had a lower age of
onset compared to the other classes (i.e. 18.1 v. 21.6 v. 22.6).
There were no differences in course or diagnoses at 2 and 6
years follow-up (see online Supplementary Table S2). Individual
symptoms of depression and anxiety did not differ between
classes (data not shown).
LCA in the combined sample of patients and healthy controls
(see online Supplementary Table S3) again showed a 3-class
model to be optimal. The classes were very similar to the original
model with regard to their respective biomarker profiles (see
online Supplementary Fig. S1). When compared across the
classes, the percentage of subjects with current psychopathology
was higher in the overweight class, whereas the percentages of
patients and controls in the lean class were equal (see online
Supplementary Table S4).
Discussion
This study aimed to use LCA in to identify subgroups with differ-
ent biomarker profiles in a large sample of patients with depres-
sive and anxiety disorders. A lean (21.6%), an average (62.2%)
and an overweight (16.2%) class were identified. Overall, the
model seemed to reflect somatic health status, which was
confirmed by the observation of similar classes when healthy con-
trols were included in the sample. Still, the fact that the subjects
with psychopathology were relatively likely to be in the ‘over-
weight’ class compared with healthy controls, indicates a possible
connection between these disorders and the overweight bio-
marker profile. Furthermore, we found that the lean group had
a significantly lower age of onset compared to the other two
groups (see Table 4). Although the mean ages of onset are all
in early adulthood and relatively close to each other, it cannot
be excluded that there may be subtle differences in etiological
mechanisms.
These bottom-up findings align with findings from research
that used a more top-down approach and showed an association
between depression and anxiety and obesity/MetS in this sample
(van Reedt Dortland et al., 2009; Van Reedt Dortland et al., 2010),
and with results from large-scale meta-analyses (Blaine, 2008;
Luppino et al., 2010; Sardinha and Nardi, 2014; Vancampfort
et al., 2014; Ghanei Gheshlagh et al., 2015; Mannan et al.,
2016). The exact mechanisms behind these associations are
unclear, partially because the (bi)directional nature of the associ-
ation is still a point of discussion (Blaine, 2008; Ghanei Gheshlagh
et al., 2015; Hiles et al., 2016; Mannan et al., 2016). Obesity might
cause depression and anxiety through social or biological
mechanisms, but it might also be that the excessive weight gain
is caused by the unhealthy lifestyle habits of patients.
Medication use is another risk factor, as it is becoming apparent
that many commonly used psychotropic medications such as
antidepressants are associated with cardiometabolic risk factors
such as insulin resistance, obesity, and dyslipidemia (Abosi
et al. 2018). Evidence from the current sample supports this
hypothesis. We found that psychotropic medication use is higher
in the overweight subtype, and previous research in this sample
showed a directional relationship between medication use and
waist circumference and MetS (Hiles et al., 2016). Another inter-
esting hypothesis is that depression and the MetS share a com-
mon cause, for instance, genetic risk factors (Bornstein et al.,
2006). Indeed, some evidence indicates that MetS and depression
are caused by similar alterations of the stress system, including the
hypothalamus-pituitary-adrenal axis, the autonomic nervous
system, the immune system, and platelet and endothelial function
(Van Reedt Dortland et al., 2010; Luppino et al., 2014; Marazziti
et al., 2014; Vancampfort et al., 2014; Vogelzangs et al., 2014).
However, we found no association between the overweight
subtype and course or diagnoses at 2- and 6-year follow-up. It
is possible that no such association exists, but there are alternative
explanations. It is possible that other causal factors (not shared
between depression and the MetS) obfuscated the results.
Furthermore, in this sample, it has been shown that especially
MDD subjects (with and without comorbid anxiety) are more
Table 2. (Continued.)
Hypothesis Variable (Abbreviation, unit) Lean (N = 311) Average (N = 910) Overweight (N = 239) p*
Thyroxine (T4, pmol/l) 15.69 (2.94) 15.44 (2.44) 15.04 (2.78) 0.008a,c
Amylase Amylase (IU/l) 289 496.10 (259 769.97) 294 556.09 (325 513.49) 319 290.70 (253 538.20) 0.290
*Based on ANOVA for continuous variables (post-hoc = Tukey) and Kruskal–Wallis tests for non-normally distributed variables (post-hoc = Dunn test).
Significant differences by class (at α < 0.05 corrected using the False Discovery Rate controlling method):
a‘lean’ v. ‘overweight’ class.
b‘average’ v. ‘overweight’ class.
c‘lean’ v. ‘average’ class.
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likely to change weight compared to controls (de Wit et al., 2015;
Gibson-Smith et al., 2016). If subsequent biomarker changes also
occurred, these subjects might have switched subtypes, and it
might be that this change in subtype would have been more
informative with respect to course than baseline subtype member-
ship. Unfortunately, the current data did not allow for investiga-
tion of subtype changes because biomarker data needed to do so
was not available at follow-up.
In accordance with previous symptom-based subtyping
research (Van Loo et al., 2012; Rhebergen et al., 2013; de Vos
et al., 2015; Wardenaar et al., 2017) this study does not provide
a bottom-up validation for the DSM-diagnosis categories of
depression and anxiety disorders as patients with different diag-
noses did not cluster into distinct biological classes. Also, in con-
trast to previous research (Cizza et al., 2012; Lamers et al., 2013;
Łojko et al., 2015; Milaneschi et al., 2017), we did not find an
association between the latent classes and atypical v. melancholic
features of depression. When comparing melancholic and atypical
symptomatology on the IDS-SR (Rush et al., 1996) between
classes, the only significant difference was that the overweight
class showed a higher percentage of atypical specifiers compared
to the lean class. However, in absolute terms, both atypical and
melancholic IDS-SR counts were highest for the overweight
class (although differences on the melancholic subscale were no
longer significant after correction for multiple comparisons).
Overall, the results indicate that biomarker heterogeneity
among depressive and/or anxiety patients mostly reflects
variations in somatic health that extend into the part of the popu-
lation without mental health problems. However, this does not
mean that part of these biological variations is not also related
to psychological health. As stated above, variations in somatic
health are known to be strongly related to variations in psycho-
pathology. Additionally, there may be smaller but still relevant
associations between specific sets of biomarkers and depression/
anxiety that were not detected in the current analyses but could
be of strong interest for the development of more personalized
etiological models. A future methodological challenge lies in
better investigating if generic somatic-health-related biological
effects can be separated from more specific psychopathology-
related biological effects. Possibilities for this may lie in the
use of more flexible clustering algorithms, but also in the combin-
ation of biomarker and clinical data in the identification of sub-
types. With regard to the biomarkers that could be investigated
deeper, the current results suggested that there were several bio-
markers that had smaller effects in the LCA results than the
MetS biomarkers, but could still be potentially interesting as tar-
gets for further research, such as inflammation-related markers
(e.g. Kynurenine, hsCRP) or sex-related markers (e.g. SHGB,
testosterone).
Strengths and limitations
Strengths of the current study included the large sample size, the
broad range of available biomarkers, and the presence of thorough
clinical assessments. However, the results should also be inter-
preted in the context of several limitations. First, the results
apply to a group of outpatients and results cannot be directly
translated to other groups (e.g. inpatients). Second, LCA makes
very strong assumptions (e.g. local independence) that enable
LCA to estimate interpretable but strongly simplified models.
However, we believe that (the violation of) the assumption of
local independence is not a driving force in our model, because
we made sure not to include strongly correlated pairs of biomar-
kers and found classes that were not defined by specific clusters of
correlated biomarkers but rather by a collection of biomarkers
from different domains (see Table 2). Third, the possible negative
Table 3. Cramer’s V values for each biological variable in the 3-class model
based on the sample of subjects with current psychopathology
Variable Cramer’s V
Waist circumference 0.606













Liver values (combined asat/alat) 0.168
Blood pressure (combined systolic/diastolic) 0.164
Tryptophan 0.156
Heart rate reactivity (combined from both stress tests) 0.154
Blood values (combined hb, ht, ethrocytes) 0.151
Ldl-cholesterol 0.148





Dexamethasone suppression test 0.107
Auci 0.091
Free thyroxine 0.091
Tumor necrosis factor alpha 0.089
Estradiol 0.082
Thyroid stimulating hormone 0.075
Amylase 0.074
Brain-derived neurotrophic factor 0.070




ASAT, aspartate aminotransferase; ALAT, alanine aminotransferase; Hb, hemoglobin; Ht,
hematocrit; AUCi, area under the curve with respect to increase; AUCg, area under the curve
with respect to the ground.
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Table 4. Distribution of characteristics across identified classes in the sample of subjects with current psychopathology
Lean (N = 311) Average (N = 910) Overweight (N = 239) p*
Demographics and covariates
Age, mean (S.D.) 40.5 (12.23) 42.1 (12.59) 43.2 (11.49) 0.033
Sex, % female (N) 66.9 (208) 66.2 (602) 66.1 (158) 0.971
Metabolic syndrome, % (n) (medication adjusted) 2.7 (8) 18.8 (167) 65.3 (154) <0.001a,b,c
Number of chronic diseases <0.001b,c
0, N (%) 135 (43.4) 381 (41.9) 69 (28.9)
1, N (%) 102 (32.8) 301 (33.1) 74 (31.0)
2, N (%) 47 (15.1) 143 (15.7) 55 (23.0)
3 + , N (%) 27 (8.7) 85 (9.3) 41 (17.1)
Lifestyle factors
Smokers, N (%) 48.2 (150) 39.9 (363) 43.1 (103) 0.035
Alcohol abuse (audit), mean (S.D.) 5.8 (6.34) 4.7 (4.97) 3.7 (5.11) <0.001a,b,c
Medication use
Psychotropics, % (N) 67.2 (209) 71.5 (651) 77.4 (182) 0.018b,c
SSRI, % (N) 22.5 (70) 26.3 (241) 28.4 (68) 0.457
TCA, % (N) 0.6 (2) 4.1 (37) 8.4 (20) <0.001b
Benzodiazepine, % (N) 22.2 (69) 24.0 (218) 28.0 (66) 0.410
Current diagnosis (last month) 0.300
Depression only, % (N) 24.8 (77) 24.1 (219) 26.4 (63)
Anxiety only, % (N) 37.0 (115) 37.1 (338) 29.7 (71)
Comorbidity, % (N) 38.3 (119) 38.5 (353) 43.9 (105)
Age of onset, mean (S.D.) 18.1 (11.15) 21.6 (12.77) 22.64 (12.87) 0.000a,b
Number of depression diagnoses 0.192
1, % (N) 46.6 (145) 48.6 (442) 50.2 (120)
2, % (N) 16.4 (51) 14.3 (130) 20.1 (48)
Number of anxiety diagnoses 0.425
1, % (N) 47.3 (147) 48.9 (445) 42.3 (101)
2, % (N) 19.0 (59) 20.4 (186) 24.3 (58)
3, % (N) 9.0 (28) 6.6 (60) 7.2 (17)
Months with depression symptoms, mean (S.D.) 21.4 (16.33) 20.3 (14.19) 21.7 (17.10) 0.206
Months with anxiety symptoms, mean (S.D.) 26.8 (19.46) 26.7 (19.57) 24.5 (18.29) 0.544
Months with avoidance symptoms, mean (S.D.) 30.3 (21.01) 30.6 (22.55) 26.6 (22.12) 0.192
Internalizing diagnoses
MDD, % (N) 53.7 (166) 53.3 (485) 63.2 (151) 0.020b,c
Minor Depression, % (N) 6.4 (20) 5.9 (54) 4.2 (10) 0.496
Dysthymia, % (N) 19.6 (61) 17.9 (163) 23.0 (55) 0.197
Social phobia, % (N) 42.8 (133) 36.8 (335) 35.6 (85) 0.126
Panic W. Agoraphobia, % (N) 21.9 (78) 25.3 (230) 23.8 (57) 0.473
Panic W.O. Agoraphobia, % (N) 10.6 (33) 10.4 (95) 11.7 (28) 0.850
Agoraphobia, % (N) 9.6 (30) 10.1 (92) 13.0 (31) 0.378
GAD, % (N) 27.3 (85) 26.9 (245) 28.0 (67) 0.941
Depression severitiy (IDS), mean (S.D.) 29.70 (11.64) 30.01 (12.11) 34.39 (12.95) <0.001b,c
Anxiety Severity (BAI), Mean (S.D.) 16.64 (9.98) 18.02 (10.48) 20.99 (12.57) <0.001b
(Continued )
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influence of underweight could not be evaluated because people
with a BMI < 18.5 were rare compared with overweight persons.
Fourth, to facilitate the analyses, continuous biomarker measure-
ments were coded to a discrete scale, possibly leading to a loss of
information. Latent Profile Analysis (using continuous variables)
usually provides a more nuanced representation of the data.
Unfortunately, this technique could not be applied to our dataset
because it is very sensitive to non-normal distributions (Morgan
et al., 2016). Fifth, coding was stratified for sex and age groups,
but other unknown/unmeasured factors were not considered.
Finally, the biological data needed to estimate the subtypes was
not available at follow-up, making it impossible to investigate sub-
type stability over time and the effects of subtype changes over
time.
In conclusion, three biological subgroups were identified with
LCA among depressive and/or anxiety patients. These subgroups
showed classes that (1) were strongly tied to general (metabolic)
health, (2) did not reflect any natural cutoffs along the lines of
the traditional diagnostic classifications, and (3) showed that
especially poor metabolic health had a strong relationship with
depression and anxiety and could, therefore, be seen as a distal
marker for these types of psychopathology.
Supplementary Material. The supplementary material for this article can
be found at https://doi.org/10.1017/S0033291718001307
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